Alnylam Pharmaceuticals

Early recognition of transthyretin #amyloidosis with cardiomyopathy (#ATTR-CM) impacts lives, yet it remains underdiagnosed.

We’re proud to support @American_Heart’s IMPACT ATTR initiative to help clinicians diagnose earlier and improve the quality and consistency of care.

Every patient story matters.

At @American_Heart (AHA) in Chicago, visit Alnylam booth 2818 to watch former professional football player Pete’s journey with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and why greater disease awareness matters.

Discover the new transthyretin #amyloidosis with cardiomyopathy (#ATTR-CM) data we’ll be presenting at upcoming congresses.

📍 First stop is the @American_Heart (AHA) #ScientificSessions26

📍 Then we’ll be heading to the @ISA_Amyloidosis Symposium #ISA2026

This #HyperoxaluriaAwarenessWeek, we’re helping raise awareness for Primary Hyperoxaluria Type 1 (PH1).

One kidney stone might seem like chance, but recurring stones in adults, or any stones in children, may point to symptoms that shouldn't be ignored. bit.ly/3UDiJRP

#PH1 #Hyperoxaluria

As Health Literacy Month comes to a close, we’re breaking down the basics of clinical trials: what they are, why they matter and the important role they play in advancing new medicines.

At Alnylam, helping people understand clinical research is one way we can better connect our science with the people we hope to serve. Watch the video to learn more.

Read more about our trials: go-alnylam.com/4sGrTze